Date08/03/2021

In June 2021, the FDA approved aducanumab (Aduhelm™) for use in treating patients with mild cognitive impairment or mild dementia stage of Alzheimer’s disease, and AGS members and other clinicians caring for older adults are being asked whether this new treatment is right for their patients. AGS has developed preliminary advice providing clinicians with the best available information to assist them in informing patients and surrogates about what is currently known about the risks and benefits of aducanumab. View the guidance here.